PuriCore Plc PuriCore Signs Vashe Marketing Agreement (4095B)
03 Abril 2013 - 12:00AM
UK Regulatory
TIDMPURI
RNS Number : 4095B
PuriCore Plc
03 April 2013
PuriCore plc
("PuriCore" or the "Company")
3 April 2013
PuriCore Signs Vashe Marketing Agreement with SteadMed
Medical
PuriCore(LSE: PURI), the water-based clean technology company,
today announces a marketing and distribution agreement with
SteadMed Medical, a leading marketer of acute and chronic wound
care products, for the Company's Vashe(R) Wound Therapy. SteadMed
will provide marketing and distribution services for Vashe in the
US, Canada, and Mexico and will target hospitals, wound care
centres, nursing homes, and home health agencies.
Under the terms of the multi-year agreement, PuriCore receives
an upfront payment of $500,000 and will receive royalties in the
high teens based on sales volumes. All intellectual property
related to Vashe Wound Therapy remains under the ownership of
PuriCore.
Vashe Wound Therapy is a safe and effective non-antibiotic
alternative wound treatment for acute and chronic wounds that is
demonstrated to be extremely gentle and hypoallergenic. Vashe has
been rigorously safety tested and is non-cytotoxic, non-irritating,
non-sensitizing, and has no oral toxicity or clinical
contraindications for use. Vashe Wound Therapy is intended for use
in cleansing, irrigating, moistening, and debriding acute and
chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis
ulcers, diabetic ulcers, post-surgical wounds, first- and
second-degree burns, abrasions, and minor irritations of the skin.
Vashe Wound Therapy is available by prescription only.
According to Global Data, the US wound care market is currently
valued at $6.2 billion and is growing at 5% per year and. By 2015,
the US wound care market is forecasted to grow to $7.5 billion.
Michael Ashton, Executive Chairman of PuriCore, said:
"Leading hospitals, wound care centres, and home healthcare
providers use Vashe Wound Therapy as a safe and effective treatment
for chronic and acute wounds, including diabetic ulcers and burns.
This agreement expands PuriCore's reach through SteadMed's
experienced sales, marketing, and clinical teams whilst enhancing
their already strong wound care portfolio in the North American
wound care market."
Michael Steadman, President and Chief Executive Officer of
SteadMed Medical, said:
"Vashe Wound Therapy is an excellent addition to our portfolio
of products that are specifically selected to address the growing
patient needs in acute and chronic wound care. We believe in
marketing the highest quality products available, positioned as
comprehensive solutions to healthcare practitioners and to the
patients they treat. Vashe Wound Therapy is a welcomed and
much-needed product for the millions of patients who suffer with
acute and chronic wounds."
About PuriCore
PuriCore plc (LSE: PURI) is a water-based clean technology
company focused on developing and commercialising proprietary
solutions that protect people from the spread of infectious
pathogens without causing harm to human health or the environment.
The Company's products are used in a broad range of markets that
depend upon effective pathogen control. PuriCore is the leading
full provider of all products and services required for a safe,
efficient, and compliant endoscope decontamination to protect
patients in UK hospitals. The Company's products are the standard
for food safety and are used for floral care in leading US
supermarket chains. PuriCore also offers a breakthrough wound
therapy solution to treat chronic and acute wounds including
diabetic ulcers and burns. PuriCore is headquartered in Malvern,
Pennsylvania, with operations in Stafford and Clevedon, UK. To
receive additional information on PuriCore, visit www.puricore.com,
which does not form part of this announcement.
About SteadMed Medical
SteadMed Medical provides innovative medical devices and
therapeutic products to hospitals, wound care centers, nursing
homes, and home health agencies with a focus on acute and chronic
wounds, skin moisturization, and incontinence care. SteadMed's
extensive portfolio of products can optimize protocols for the care
and management of skin and skin breakdown. The company has
dedicated field representatives, customer service and clinical
personnel who bring comprehensive solutions to those with wound and
skin care complications. To receive additional information on
SteadMed Medical, visit www.steadmed.com.
Enquiries:
UK US
FTI Consulting Sage Strategic Marketing
Susan Stuart/Simon Conway/Victoria Jennifer Guinan
Foster Mitchell
+44 (0) 20 7831 3113 +1 610.410.8111
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions shareholders and prospective shareholders not
to place undue reliance on these forward-looking statements, which
reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRNKBDNDBKBPQK
Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024